Testosterone Deficiency and Prostate Cancer: Emerging Recognition of an Important and Troubling Relationship

European Urology

Volumn 52, Issue 3, 2007, Pages 623-625

  Morgentaler, Abraham ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; FINASTERIDE; FOLLITROPIN; LUTEINIZING HORMONE; TESTOSTERONE;

AGING; CANCER RECURRENCE; CANCER RISK; EDITORIAL; GLEASON SCORE; HORMONE BLOOD LEVEL; HUMAN; HYPOGONADISM; LONGITUDINAL STUDY; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TRANSURETHRAL RESECTION;

BIOPSY; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; TESTOSTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 34547177850     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.04.005     Document Type: Editorial

References (10)

1. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol 50 (2006) 935-939
2. Yamamoto S., Yonese J., Kawakami S., et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol. 52 (2007) 696-701
3. Platz E.A., Leitzmann M.F., Rifai N., et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 14 (2005) 1262-1269
4. Morgentaler A., Bruning III C.O., and DeWolf W.C. Incidence of occult prostate cancer among men with low total or free serum testosterone. JAMA 276 (1996) 1904-1906
5. Morgentaler A., and Rhoden E.L. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen of 4.0 ng/ml or less. Urology 68 (2006) 1263-1267
6. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4 ng per milliliter. N Eng J Med 350 (2004) 2239-2246
7. Nishiyama T., Ikarashi T., Hashimoto Y., Suzuki K., and Takahashi K. Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score. J Urol 176 (2006) 1387-1391
8. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
9. Marks L.S., Mazer N.A., Mostaghel E., et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 296 (2006) 2351-2361
10. Sarosdy M.F. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer 109 (2007) 536-541